Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest™ (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH)

Virchows Archiv

Volumn 454, Issue 3, 2009, Pages 241-248

  Mayr, Doris ^a   Heim, Sibylle ^a   Werhan, Cedric ^b   Zeindl Eberhart, Evelyn ^a   Kirchner, Thomas ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Ventana   (France)

Author keywords

BenchMark; Breast cancer; FISH; Her 2 neu immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; AUTOMATION; BREAST CARCINOMA; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MANUAL LABOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; REAGENT KITS, DIAGNOSTIC; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING;

EID: 65149101768     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-009-0728-8     Document Type: Article

References (23)

1. A Berchuck A Kamel R Whitaker 1990 Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer Cancer Res 50 4087 4091 (Pubitemid 20225635)
2. MF Press MC Pike G Hung 1994 Amplification and overexpression of HER 2/neu in carcinomas of the salivary gland: correlation with poor prognosis Cancer Res 54 5675 5682 (Pubitemid 24346266)
3. MR Raspollini G Amunni A Villanucci 2006 HER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival Appl Immunohistochem Mol Morphol 14 181 186 (Pubitemid 43941182)
4. SC Formenti D Spicer K Skinner 2002 Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer Int J Radiat Oncol Biol Phys 52 397 405 (Pubitemid 34170845)
5. G Gasparini R Longo F Torino 2005 Therapy of breast cancer with molecular targeting agents Ann Oncol 16 Suppl 4 iv28 iv36 (Pubitemid 43084943)
6. BA Gusterson RD Gelber A Goldhirsch 1992 Prognostic importance of c erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group J Clin Oncol 10 1049 1056
7. MD Pegram G Pauletti DJ Slamon 1998 HER-2/neu as a predictive marker of response to breast cancer therapy Breast Cancer Res Treat 52 65 77 (Pubitemid 29056086)
8. S Paik J Bryant E Tan-Chiu 2002 Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience J Natl Cancer Inst 94 852 854 (Pubitemid 34705057)
9. A Rhodes B Jasani E Anderson 2002 Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries Am J Clin Pathol 118 408 417 (Pubitemid 37046339)
10. A Rhodes B Jasani J Couturier 2002 A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer Am J Clin Pathol 117 81 89 (Pubitemid 34052476)
11. DAKO A/S, F. Hoffmann-La Roche Ltd (eds) (2002) Atlas of interpretation of HercepTestTM staining. (2000)
12. AC Wolff ME Hammond JM Schwartz 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 145 (Pubitemid 350003059)
13. D Mayr J Diebold 2000 Grading of ovarian carcinomas Int J Gynecol Pathol 19 348 353
14. G Pauletti W Godolphin MF Press 1996 Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization Oncogene 13 63 72 (Pubitemid 26248546)
15. A Bankfalvi R Simon B Brandt 2000 Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use Histopathology 37 411 419
16. MF Press DJ Slamon KJ Flom 2002 Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens J Clin Oncol 20 3095 3105
17. RR Tubbs JD Pettay PC Roche 2001 Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false positives do not get the message J Clin Oncol 19 2714 2721 (Pubitemid 32441377)
18. M Dowsett AM Hanby R Laing 2007 HER2 testing in the UK: consensus from a national consultation J Clin Pathol 60 685 689 (Pubitemid 46975226)
19. AP Gouvea F Milanezi SJ Olson 2006 Selecting antibodies to detect Her2 overexpression by immunohistochemistry in invasive mammary carcinomas Appl Immunohistochem Mol Morphol 14 103 108
20. WC Powell DG Hicks N Prescott 2007 A new rabbit monoclonal antibody (4B5) for immunohistochemical (IHC) determination of Her2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility Appl Immunohistochem Mol Morphol 15 94 102 (Pubitemid 46673324)
21. SAV Ricardo F Milanezi ST Carvalho 2008 Her2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast J Clin Path 60 1001 1005 (Pubitemid 47441932)
22. M Brunelli E Manfrin G Martignoni 2008 Her-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for Herceptin therapy Am J Clin Pathol 129 907 911
23. CB Moeder JM Giltnane M Harigopal 2007 Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray-based assessment of outcome J Clin Oncol 25 5418 5425 (Pubitemid 350232218)